Ritonavir

• CAT Number: A000960
• CAS Number: 155213-67-5
• Molecular Formula: C37H48N6O5S2
• Molecular Weight: 720.9
• Purity: ≥95%
• Target: HIV Protease
• Solubility: Soluble in DMSO > 10 mM
• Storage: -20°C
• InChI: 1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)
• InChIKey: NCDNCNXCDXHOMX-XGKFQTDJSA-N
• SMILES: CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O

Ritonavir is an inhibitor of HIV-1 protease used to treat HIV infection and AIDS. It is widely used as a booster of other protease inhibitors. More specifically, ritonavir is used to inhibit a particular liver enzyme that normally metabolizes protease inhibitors, CYP3A4.

Reference

1: Freise KJ, Hu B, Salem AH. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. Eur J Clin Pharmacol. 2018 Jan 4. doi: 10.1007/s00228-017-2403-3. [Epub ahead of print] PubMed PMID: 29302721.
2: Mantripragada MKVVN, Rao SV, Nutulapati VVS, Mantena BPV. Simultaneous Determination of Impurities of Atazanavir and Ritonavir in Tablet Dosage Form by Using Reversed-Phase Ultra Performance Liquid Chromatographic Method. J Chromatogr Sci. 2017 Dec 29. doi: 10.1093/chromsci/bmx110. [Epub ahead of print] PubMed PMID: 29300835.
3: Le Meur L, Tantet C, Lê MP, Desselas E, Bonnal C, Lillo-Le-Louet A, Sonneville R, Massias L, Giraud J, Descamps D, Yazdanpanah Y, Lariven S, Peytavin G. Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis. J Antimicrob Chemother. 2017 Dec 25. doi: 10.1093/jac/dkx495. [Epub ahead of print] PubMed PMID: 29294026.
4: Sanai FM, Alghamdi AS, Afghani AA, Alswat K, AlZanbagi A, Alghamdi MN, AlMousa A, Aseeri M, Assiri AM, Babatin MA. High Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Hepatitis C Genotypes 4 and 1-infected Patients with Severe Chronic Kidney Disease. Liver Int. 2017 Dec 29. doi: 10.1111/liv.13674. [Epub ahead of print] PubMed PMID: 29288514.
5: Barber TJ, Imaz A, Boffito M, Niubó J, Pozniak A, Fortuny R, Alonso J, Davies N, Mandalia S, Podzamczer D, Gazzard B. CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study. J Neurovirol. 2017 Dec 26. doi: 10.1007/s13365-017-0600-6. [Epub ahead of print] PubMed PMID: 29280108.
6: Samuels ER, Sevrioukova I. Inhibition of Human CYP3A4 by Rationally Designed Ritonavir-Like Compounds: Impact and Interplay of the Side Group Functionalities. Mol Pharm. 2018 Jan 2;15(1):279-288. doi: 10.1021/acs.molpharmaceut.7b00957. Epub 2017 Dec 12. PubMed PMID: 29232137.
7: Talal AH, Dumas EO, Bauer B, Rejman RM, Ocque A, Morse GD, Lucic D, Cloherty GA, King J, Zha J, Zhang H, Cohen DE, Shulman N, Pawlotsky JM, Hézode C. Hepatic Pharmacokinetics and Pharmacodynamics with Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage. J Infect Dis. 2017 Sep 27. doi: 10.1093/infdis/jix495. [Epub ahead of print] PubMed PMID: 29228392.
8: Seang S, Schneider L, Nguyen T, Lê MP, Soulie C, Calin R, Caby F, Valantin MA, Tubiana R, Assoumou L, Marcelin AG, Peytavin G, Katlama C. Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia. J Antimicrob Chemother. 2017 Dec 5. doi: 10.1093/jac/dkx417. [Epub ahead of print] PubMed PMID: 29216346.
9: Yoshimura Y, Miyata N, Komatsu H, Tachikawa N. Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case. AIDS. 2018 Jan 2;32(1):128-129. doi: 10.1097/QAD.0000000000001665. PubMed PMID: 29210779.
10: Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov-Dec;18(5-6):214-222. doi: 10.1080/15284336.2017.1402144. PubMed PMID: 29210626.